NO20011304L - Fremgangsmåte for å nedregulere osteoprotegerin ligand aktivitet - Google Patents

Fremgangsmåte for å nedregulere osteoprotegerin ligand aktivitet

Info

Publication number
NO20011304L
NO20011304L NO20011304A NO20011304A NO20011304L NO 20011304 L NO20011304 L NO 20011304L NO 20011304 A NO20011304 A NO 20011304A NO 20011304 A NO20011304 A NO 20011304A NO 20011304 L NO20011304 L NO 20011304L
Authority
NO
Norway
Prior art keywords
opgl
osteoprotegerin ligand
nucleic acids
downregulating
ligand activity
Prior art date
Application number
NO20011304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011304D0 (no
Inventor
Torben Halkier
Jesper Haaning
Original Assignee
M & E Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M & E Biotech As filed Critical M & E Biotech As
Publication of NO20011304D0 publication Critical patent/NO20011304D0/no
Publication of NO20011304L publication Critical patent/NO20011304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
NO20011304A 1998-09-15 2001-03-14 Fremgangsmåte for å nedregulere osteoprotegerin ligand aktivitet NO20011304L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (2)

Publication Number Publication Date
NO20011304D0 NO20011304D0 (no) 2001-03-14
NO20011304L true NO20011304L (no) 2001-05-15

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011304A NO20011304L (no) 1998-09-15 2001-03-14 Fremgangsmåte for å nedregulere osteoprotegerin ligand aktivitet

Country Status (24)

Country Link
US (2) US6645500B1 (hu)
EP (1) EP1114166B1 (hu)
JP (1) JP2002525060A (hu)
KR (1) KR100671036B1 (hu)
CN (1) CN1318105A (hu)
AT (1) ATE291628T1 (hu)
AU (1) AU754971B2 (hu)
CA (1) CA2343654A1 (hu)
CZ (1) CZ2001789A3 (hu)
DE (1) DE69924392T2 (hu)
EE (1) EE200100149A (hu)
ES (1) ES2239457T3 (hu)
HK (1) HK1040261A1 (hu)
HR (1) HRP20010188A2 (hu)
HU (1) HUP0103578A3 (hu)
ID (1) ID28386A (hu)
IL (2) IL141588A0 (hu)
NO (1) NO20011304L (hu)
NZ (1) NZ510508A (hu)
PL (1) PL196790B1 (hu)
PT (1) PT1114166E (hu)
SK (1) SK3062001A3 (hu)
TR (1) TR200100737T2 (hu)
WO (1) WO2000015807A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
SK3062001A3 (en) * 1998-09-15 2002-02-05 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2380007A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
RS51164B (sr) * 2000-02-21 2010-10-31 H. Lundbeck A/S. Postupak za smanjenje količine amiloida
MXPA02007796A (es) * 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
WO2001091793A1 (en) * 2000-05-26 2001-12-06 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002015846A2 (en) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JPWO2002024228A1 (ja) * 2000-09-21 2004-01-29 株式会社先端科学技術インキュベーションセンター 破骨細胞形成を制御する方法
AU2001293030B2 (en) 2000-09-22 2007-07-19 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of NF-kB
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
EP1757619B1 (en) 2001-04-03 2010-02-17 Société des Produits Nestlé S.A. Osteoprotegerin in milk
BRPI0210579B8 (pt) * 2001-06-26 2021-05-25 Amgen Fremont Inc anticorpo e composição farmacêutica
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein
EP1576088A4 (en) 2002-01-04 2006-09-06 Xencor Inc DOMINANT NEGATIVE PROTEINS AND METHOD THEREFOR
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2003297833A1 (en) 2002-12-10 2004-06-30 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
US10035834B2 (en) * 2008-06-18 2018-07-31 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2024054566A1 (en) * 2022-09-07 2024-03-14 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU7639994A (en) 1993-08-27 1995-03-21 Dow Chemical Company, The Process for the separation of enantiomers
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
DE69738811D1 (de) * 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
EP0946725B1 (en) * 1996-12-23 2011-01-26 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
SK3062001A3 (en) * 1998-09-15 2002-02-05 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
IL141588A (en) 2008-07-08
PT1114166E (pt) 2005-08-31
PL196790B1 (pl) 2008-01-31
HUP0103578A3 (en) 2005-11-28
EE200100149A (et) 2002-08-15
NZ510508A (en) 2005-05-27
ID28386A (id) 2001-05-17
KR100671036B1 (ko) 2007-01-18
CZ2001789A3 (cs) 2001-08-15
EP1114166B1 (en) 2005-03-23
DE69924392D1 (de) 2005-04-28
JP2002525060A (ja) 2002-08-13
ATE291628T1 (de) 2005-04-15
HRP20010188A2 (en) 2002-04-30
ES2239457T3 (es) 2005-09-16
TR200100737T2 (tr) 2001-07-23
IL141588A0 (en) 2002-03-10
US20040115199A1 (en) 2004-06-17
US6645500B1 (en) 2003-11-11
HK1040261A1 (zh) 2002-05-31
CA2343654A1 (en) 2000-03-23
PL346698A1 (en) 2002-02-25
WO2000015807A1 (en) 2000-03-23
SK3062001A3 (en) 2002-02-05
CN1318105A (zh) 2001-10-17
HUP0103578A2 (hu) 2002-01-28
DE69924392T2 (de) 2006-03-09
AU5617399A (en) 2000-04-03
EP1114166A1 (en) 2001-07-11
AU754971B2 (en) 2002-11-28
KR20010085807A (ko) 2001-09-07
NO20011304D0 (no) 2001-03-14

Similar Documents

Publication Publication Date Title
NO20011304L (no) Fremgangsmåte for å nedregulere osteoprotegerin ligand aktivitet
EP1162272A3 (en) Generation of immune responses to prostate-specific antigen (SPA)
AU2001254624A1 (en) Human coagulation factor vii variants
HK1110876A1 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2241918A1 (en) Peanut allergens and methods
NO960309L (no) Agonister og antagonister for humaninterleukin-10
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
CA2272407A1 (en) Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
NO20015021L (no) Fremgangsmåte til å nedregulere IL-5 aktivitet
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
YU19701A (sh) Postupak za regulisanje na niže osteoprotegerinske ligandne aktivnosti
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
EP1443055A3 (en) Interleukins-21 and 22
EP1541587A3 (en) Method for down-regulating osteoprotegerin ligand activity
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
AUPM772494A0 (en) Improvements in production of proteins in host cells
WO2002040059A3 (en) Methods and compositions for inducing cell-mediated immune responses
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
WO2002014501A3 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
WO1998018942A3 (en) Novel human rab proteins
EA200501773A1 (ru) Детоксифицированный tnf и способ получения
WO2002088380A3 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application